2025
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatientsEmbryonic and fetal development of the human knee with an emphasis on the posterior cruciate ligament: a literature review
Levitt S, Park N, Cheng R, Ayhan E, Zazulak B, Joo P, Islam W, Jokl P, Katz L, Medvecky M. Embryonic and fetal development of the human knee with an emphasis on the posterior cruciate ligament: a literature review. Annals Of Joint 2025, 10: 10-10. PMID: 39981425, PMCID: PMC11836755, DOI: 10.21037/aoj-24-36.Peer-Reviewed Original ResearchCongenital anomaliesFetal developmentPosterior cruciate ligamentClinical conditionsMeniscofemoral ligamentCruciate ligamentFetal formationFetal appearanceStaging systemHuman embryosMesenchymal tissueWeeks of developmentDevelopment of articulationEmbryological developmentIntraarticular structuresAdult kneesEmbryo sectionsMorphological criteriaLigamentKnee
2024
Atrial cardiomyopathy revisited—evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS)
Goette A, Corradi D, Dobrev D, Aguinaga L, Cabrera J, Chugh S, de Groot J, Soulat-Dufour L, Fenelon G, Hatem S, Jalife J, Lin Y, Lip G, Marcus G, Murray K, Pak H, Schotten U, Takahashi N, Yamaguchi T, Zoghbi W, Nattel S, Mont L, Akar J, Akoum N, Althoff T, Diaz J, Guichard J, Jadidi A, Kalman J, Lim H, Teixeira R. Atrial cardiomyopathy revisited—evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). EP Europace 2024, 26: euae204. PMID: 39077825, PMCID: PMC11431804, DOI: 10.1093/europace/euae204.Peer-Reviewed Original ResearchConceptsEuropean Heart Rhythm AssociationLatin American Heart Rhythm SocietyHeart Rhythm SocietyClinical consensus statementAtrial fibrillationConsensus statementDevelopment of atrial fibrillationConsensus documentAtrial cardiomyopathyStaging systemElectrophysiological changesClinical validationExpert working groupAtrial geometryHeartDevelopment and validation of an individualized nomogram for gastric cancer patients treated with perioperative chemotherapy followed by radical surgery
Wang Y, Zhang S, Ding B, Tang Z, Ji Y, Yu Y, Cui Y, Wang X, Sun Y, Liu T. Development and validation of an individualized nomogram for gastric cancer patients treated with perioperative chemotherapy followed by radical surgery. Translational Gastroenterology And Hepatology 2024, 0: 0-0. PMID: 39091661, PMCID: PMC11292059, DOI: 10.21037/tgh-23-75.Peer-Reviewed Original ResearchLocally advanced GC patientsProgression-free survivalAdvanced GC patientsOverall survivalDecision curve analysisTumor-node-metastasisRadical surgeryGC patientsReceiver operating characteristicNeoadjuvant chemotherapyPerioperative chemotherapyPrognostic factorsStaging systemC-indexTumor-node-metastasis (TNM) staging systemGastric cancerLocally advanced gastric cancerPatients treated with perioperative chemotherapyMultivariate Cox regression modelAssociated with clinical characteristicsAdvanced gastric cancerRisk group classificationExternal validation cohortIndependent external cohortLow-risk groupAutomated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 34: 6940-6952. PMID: 38536464, PMCID: PMC11399284, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeTreatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage
Hanson I, Rusia A, Palomo A, Tawney A, Pow T, Dixon S, Meraj P, Sievers E, Johnson M, Wohns D, Ali O, Kapur N, Grines C, Burkhoff D, Anderson M, Lansky A, Naidu S, Basir M, O'Neill W. Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage. Journal Of The American Heart Association 2024, 13: e031803. PMID: 38293995, PMCID: PMC11056148, DOI: 10.1161/jaha.123.031803.Peer-Reviewed Original ResearchConceptsSociety for Cardiovascular AngiographyCardiovascular AngiographyAcute myocardial infarctionIII studiesCardiogenic shockStage CPercutaneous coronary interventionMyocardial infarctionPostapproval studiesCoronary interventionImpella supportKaplan-Meier survival curve analysisSociety of Cardiovascular AngiographyThirty-day survivalResponse to therapyCohort of patientsStudy of patientsPredictors of mortalitySurvival curve analysisTreatment of acute myocardial infarctionPredictive of mortalitySeverity of shockSingle-armThirty-dayStaging system
2023
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendationsPrognostic Utility of Left Atrial Strain to Predict Thrombotic Events and Mortality in Amyloid Cardiomyopathy
Akintoye E, Majid M, Klein A, Hanna M. Prognostic Utility of Left Atrial Strain to Predict Thrombotic Events and Mortality in Amyloid Cardiomyopathy. JACC Cardiovascular Imaging 2023, 16: 1371-1383. PMID: 37940322, DOI: 10.1016/j.jcmg.2023.01.015.Peer-Reviewed Original ResearchConceptsThrombotic eventsAmyloid cardiomyopathyAtrial fibrillationLA contractileLA strainLA contractile strainModest discriminatory abilityPrognostic staging systemRisk stratification toolLeft Atrial StrainHigh thrombotic riskAtrial strainPrognostic utilityStratification toolPrognostic valueC-statisticRespective HRsStaging systemThrombotic riskACM patientsSD decreaseAF casesPredictive valuePatientsDiscriminatory ability
2022
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx
Kantor O, Burstein HJ, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EA. Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. Annals Of Surgical Oncology 2022, 29: 8016-8023. PMID: 35900648, DOI: 10.1245/s10434-022-12225-5.Peer-Reviewed Original ResearchConceptsRecurrence-free intervalBreast cancer patientsRecurrence scoreTAILORx trialEndocrine therapyCancer patientsHormone receptor-positive breast cancer patientsBackgroundThe American Joint CommitteePositive breast cancer patientsCurrent AJCC staging systemHuman epidermal growth factor receptorBreast Recurrence ScoreKaplan-Meier methodAmerican Joint CommitteeAJCC staging systemEpidermal growth factor receptorGrowth factor receptorMedian followT1-2N0T3 diseasePrognostic stagingStaging systemStaging criteriaBreast cancerResultsThe studyOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolizationAdjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future
Strazzabosco M, Cabibbo G, Colombo M. Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future. Gastroenterology 2022, 162: 2106-2108. PMID: 35122767, DOI: 10.1053/j.gastro.2022.01.035.Peer-Reviewed Original Research
2021
Expanding Criteria for Prognostic Stage IA in Hormone Receptor–Positive Breast Cancer
Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor–Positive Breast Cancer. Journal Of The National Cancer Institute 2021, 113: 1744-1750. PMID: 34010423, PMCID: PMC8634483, DOI: 10.1093/jnci/djab095.Peer-Reviewed Original ResearchConceptsDisease-specific survivalStage IA patientsStage IAIA patientsPrognostic stagingBreast cancerFive-year disease-specific survivalHormone receptor-positive breast cancerHER2-negative breast cancerReceptor-positive breast cancerN0-1 diseaseN0-1 patientsRecurrence Score resultsEnd Results (SEER) dataAmerican Joint CommitteeAJCC staging systemAJCC eighth editionT1-2N1Primary outcomePrognostic significanceStaging systemTNM categoriesT categoryRS resultsN categoryA Histopathologic Scoring System for Perineural Invasion Correlates With Adverse Outcomes in Patients With Cutaneous Squamous Cell Carcinoma.
Totonchy MB, McNiff JM, Suozzi KC, Leffell DJ, Christensen SR. A Histopathologic Scoring System for Perineural Invasion Correlates With Adverse Outcomes in Patients With Cutaneous Squamous Cell Carcinoma. Dermatologic Surgery 2021, 47: 445-451. PMID: 33795563, DOI: 10.1097/dss.0000000000002923.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaPerineural invasionSquamous cell carcinomaAdverse outcomesNerve diameterHistopathologic featuresPNI scoreCell carcinomaExtratumoral perineural invasionRetrospective cohort studyCurrent staging systemHistopathologic scoring systemTumor-related deathNumber of nervesLogistic regression analysisMedian followNerve involvementCohort studyLocal recurrenceSurgical excisionStaging systemRisk factorsMedian numberHistopathologic slidesNerve structuresEvaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system
Lee NCJ, Eskander A, Miccio JA, Park HS, Shah C, Rutenberg M, Hosni A, Husain ZA. Evaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system. Oral Oncology 2021, 114: 105137. PMID: 33422859, DOI: 10.1016/j.oraloncology.2020.105137.Peer-Reviewed Original ResearchConceptsNeck soft tissue sarcomasTumor size cutNational Cancer DatabaseSoft tissue sarcomasMultivariable analysisTissue sarcomasFive-year overall survivalNeoadjuvant therapy patientsT1-3 tumorsEnd Results (SEER) databaseAdjacent structuresEvaluation of headPaucity of dataNCDB cohortSEER cohortPrimary surgeryOverall survivalWorsened survivalAdverse prognosticatorPrognostic differencesResults databaseStaging systemT4 classificationTumor stageCancer Database
2020
Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy
Zhang X, Jain D. Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy. Annals Of The New York Academy Of Sciences 2020, 1482: 163-176. PMID: 32892349, DOI: 10.1111/nyas.14462.Peer-Reviewed Original ResearchConceptsNeoadjuvant therapyEsophageal cancerEsophageal carcinomaRecent American Joint CommitteePreoperative neoadjuvant therapyThorough pathologic assessmentTumor regression gradingAdvanced esophageal carcinomaAmerican Joint CommitteeCancer (AJCC) staging systemTumor regression gradeAccurate tumor stagingValuable prognostic informationRegression gradingSurgical resectionLymph nodesPathologic assessmentRegression gradeHistologic typePathologic evaluationResidual tumorPoor prognosisCell carcinomaGastrointestinal carcinomasStaging systemA novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients
Liao M, Zeng F, Li Y, Gao Q, Yin M, Deng G, Chen X. A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. Scientific Reports 2020, 10: 12462. PMID: 32719391, PMCID: PMC7385638, DOI: 10.1038/s41598-020-69330-2.Peer-Reviewed Original ResearchConceptsImmune-related genesMelanoma patientsGene Expression Omnibus databaseImmune-related gene signatureConventional staging systemsLow-risk patientsIndependent prognostic factorDecision curve analysisCancer Genome Atlas (TCGA) databaseTwo-gene signatureSignature gene expressionIRG signatureOverall survivalPrognostic factorsClinical parametersPrediction nomogramStaging systemTNM stagePatient prognosisConcordance indexPrognostic performanceIndividual prognosisInvasive typeSkin cancerImmune systemLung Cancer Staging
Tanoue LT. Lung Cancer Staging. Clinics In Chest Medicine 2020, 41: 161-174. PMID: 32402353, DOI: 10.1016/j.ccm.2020.02.006.Peer-Reviewed Original ResearchConceptsAnatomic stagingStaging systemLung cancerAnatomic staging systemMultiple pulmonary sitesEvaluation of patientsExtent of diseaseLung cancer stagingMetastatic diseaseSurvival outcomesImmunologic informationPulmonary sitesPrimary tumorRegional nodesCancer stagingAppropriate careTNM componentsStagingCancerDiseasePatientsPrognosisTumorsEnvironment-level factorsCareChromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.Peer-Reviewed Original ResearchConceptsHigh-risk chromosomal abnormalitiesOverall survivalMultiple myelomaChromosome 1 abnormalitiesCox proportional hazards regression modelHigh-risk multiple myelomaProportional hazards regression modelsFlatiron Health databaseR-ISS stageMedian overall survivalFirst-line therapyDays of diagnosisInferior overall survivalInternational Staging SystemKaplan-Meier methodSurvival of patientsWorse overall survivalLog-rank testHazards regression modelsCommon genetic aberrationsElectronic health recordsEligible patientsContemporary cohortImmunomodulatory agentsStaging systemExpanding criteria for prognostic stage IA disease in HR+ breast cancer.
Kantor O, King T, Shak S, Russell C, Giuliano A, Hortobagyi G, Burstein H, Winer E, Sparano J, Mittendorf E. Expanding criteria for prognostic stage IA disease in HR+ breast cancer. Journal Of Clinical Oncology 2020, 38: 550-550. DOI: 10.1200/jco.2020.38.15_suppl.550.Peer-Reviewed Original ResearchStage IA diseaseRecurrence scoreIA diseaseN categoryOncotype DX recurrence scoreNode-positive diseaseAJCC staging systemDX recurrence scoreRS resultsRS 11Median followDSS ratesPositive diseaseSEER databaseReceptor statusStaging systemEvidence of utilityScore 11Breast cancerTrial dataDiseaseAdditional studiesPatientsStagingDSS
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance index
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply